Valued at $10.2 billion by market cap, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) operates as a clinical-stage pharmaceutical company. It focuses on discovering and developing messenger RNA (mRNA) based therapies and vaccines for the treatment of autoimmune conditions, infectious diseases, immuno-oncology, rare, and cardiovascular diseases. Companies worth $10 billion or more are generally referred to as “large-cap stocks.” Moderna fits right into that category, with its market cap exceeding the ...